TABLE 2.
Correlations between 6-month delta-BMI change and clinicopathological factors
| ≥15 % loss [n = 19 (2.9 %)] |
7.5–14.9 % loss [n = 61 (9.2 %)] |
<7.5 % lossa [n = 272 (40.9 %)] |
<7.5 % gain [n = 201 (30.2 %)] |
7.5–14.9 % gain [n = 20 (3.0 %)] |
≥15 % gain [n = 12 (1.8 %)] |
p value | |
|---|---|---|---|---|---|---|---|
| Age (years) | 56.5 (±8.7) | 50.8 (±9.9) | 53.2 (±10.1) | 51.0 (±10.3) | 54.3 (±10.3) | 55.9 (±11.1) | 0.034 |
| <50 | 3 (15.8) | 27 (44.3) | 89 (32.7) | 82 (40.8) | 5 (25) | 4 (33.3) | |
| ≥50 | 16 (84.2) | 34 (55.7) | 183 (67.3) | 119 (59.2) | 15 (75) | 8 (66.7) | |
| Ethnicity | 0.008 | ||||||
| Caucasian | 3 (15.8) | 12 (19.7) | 28 (10.3) | 16 (8.0) | 2 (10) | 1 (8.3) | |
| African | 2 (10.5) | 3 (4.9) | 14 (5.1) | 4 (2.0) | 0 | 3 (25.0) | |
| Hispanic | 11 (57.9) | 37 (60.7) | 192 (70.6) | 152 (75.6) | 16 (80) | 4 (33.3) | |
| Asian | 3 (15.8) | 9 (14.8) | 38 (14.0) | 29 (14.4) | 2 (10) | 4 (33.3) | |
| Pre-treatment BMI | 36.6 (±10.3) | 40.1 (±12.8) | 36.1 (±9.1) | 34.7 (±9.1) | 30.9 (±5.9) | 26.0 (±5.3) | <0.001 |
| <30 | 5 (26.3) | 14 (23.0) | 74 (27.2) | 70 (34.8) | 10 (50) | 11 (91.7) | |
| 30–39.9 | 9 (47.4) | 19 (31.1) | 116 (42.6) | 80 (39.8) | 9 (45) | 1 (8.3) | |
| ≥40 | 5 (26.3) | 28 (45.9) | 82 (30.1) | 51 (25.4) | 1 (5) | 0 | |
| Hypertension | 0.026 | ||||||
| No | 6 (31.6) | 32 (52.5) | 112 (41.2) | 99 (49.3) | 9 (45) | 10 (83.3) | |
| Yes | 13 (68.4) | 29 (47.5) | 160 (58.8) | 102 (50.7) | 11 (55) | 2 (16.7) | |
| Diabetes mellitus | 0.11 | ||||||
| No | 12 (63.2) | 42 (68.9) | 170 (62.5) | 146 (72.6) | 13 (65) | 11 (91.7) | |
| Yes | 7 (36.8) | 19 (31.1) | 102 (37.5) | 55 (27.4) | 7 (35) | 1 (8.3) | |
| Hypercholesterolemia | 0.53 | ||||||
| No | 15 (78.9) | 50 (82.0) | 204 (75) | 150 (74.6) | 17 (85) | 11 (91.7) | |
| Yes | 4 (21.1) | 11 (18.0) | 68 (25) | 51 (25.4) | 3 (15) | 1 (8.3) | |
| Histologic subtype | 0.035 | ||||||
| Endometrioid | 13 (68.4) | 49 (80.3) | 223 (82.0) | 176 (87.6) | 16 (80) | 6 (50) | |
| Serous | 2 (10.5) | 4 (6.6) | 12 (4.4) | 9 (4.5) | 2 (10) | 2 (16.7) | |
| Clear cell | 1 (5.3) | 1 (1.6) | 4 (1.5) | 4 (2.0) | 2(10) | 0 | |
| Mixed | 3 (15.8) | 7(11.5) | 30 (11.0) | 10 (5.0) | 0 | 4 (33.3) | |
| Others | 0 | 0 | 3 (1.1) | 2 (1.0) | 0 | 0 | |
| Grade | 0.001 | ||||||
| 1 | 4 (21.1) | 29 (47.5) | 148 (54.4) | 125 (62.2) | 9 (45) | 2 (16.7) | |
| 2 | 5 (26.3) | 12 (19.7) | 68 (25) | 45 (22.4) | 5 (25) | 5 (41.7) | |
| 3 | 10 (52.6) | 20 (32.8) | 56 (20.6) | 31 (15.4) | 6 (30) | 5 (41.7) | |
| Stage | <0.001 | ||||||
| I | 7 (36.8) | 36 (59.0) | 204 (75.0) | 158 (78.6) | 10 (50) | 2 (16.7) | |
| II | 0 | 7 (11.5) | 19 (7.0) | 15 (7.5) | 2 (10) | 1 (8.3) | |
| III | 7 (36.8) | 13 (21.3) | 34 (12.5) | 19 (9.5) | 3 (15) | 4 (33.3) | |
| IV | 5 (26.3) | 5 (8.2) | 15 (5.5) | 9 (4.5) | 5 (20) | 5 (41.7) | |
| Postoperative radiotherapy | 0.038 | ||||||
| None | 11 (57.9) | 35 (57.4) | 175 (64.3) | 146 (72.6) | 13 (65) | 5 (41.7) | |
| ICBT alone | 1 (5.3) | 6 (9.8) | 45 (16.5) | 23 (11.4) | 2 (10) | 3 (25) | |
| WPRT ± ICBT | 7 (36.8) | 20 (32.8) | 52 (19.1) | 32 (15.9) | 5 (25) | 4 (33.3) | |
| Postoperative chemotherapy | <0.001 | ||||||
| None | 5 (26.3) | 37 (60.7) | 211 (77.6) | 163 (81.1) | 10 (50) | 5 (41.7) | |
| Carboplatin + paclitaxel | 12 (63.2) | 22 (36.1) | 57 (21.0) | 32 (15.9) | 10 (50) | 7 (58.3) | |
| Other | 2 (10.5) | 2 (3.3) | 4 (1.5) | 6 (3.0) | 0 | 0 |
Data are expressed as mean (±SD) or n (%)
One-way ANOVA or χ2 test for p-values. Significant p values are shown in bold
a
Including cases with no interval BMI change
BMI body mass index, ICBT intracavitary brachytherapy, WPRT whole pelvic radiotherapy, ANOVA analysis of variance, SD standard deviation